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Abstract
Background: Since enzyme replacement therapy for Gaucher disease (MIM#230800) has become available, both
awareness of and the natural history of the disease have changed. However, there remain unmet needs such as the
identification of patients at risk of developing bone crisis during therapy and late complications such as cancer or
parkinsonism. The Spanish Gaucher Disease Registry has worked since 1993 to compile demographic, clinical,
genetic, analytical, imaging and follow-up data from more than 400 patients. The aims of this study were to
discover correlations between patients’ characteristics at diagnosis and to identify risk features for the development
of late complications; for this a machine learning approach involving correlation networks and decision trees
analyses was applied.
Results: A total of 358 patients, 340 type 1 Gaucher disease and 18 type 3 cases were selected. 18% were
splenectomyzed and 39% had advanced bone disease. 81% of cases carried heterozygous genotype. 47% of them
were diagnosed before the year 2000. Mean age at diagnosis and therapy were 28 and 31.5 years old (y.o.)
respectively. 4% developed monoclonal gammopathy undetermined significance or Parkinson Disease, 6% cancer,
and 10% died before this study. Previous splenectomy correlates with the development of skeletal complications
and severe bone disease (p = 0.005); serum levels of IgA, delayed age at start therapy (> 9.5 y.o. since diagnosis) also
correlates with severe bone disease at diagnosis and with the incidence of bone crisis during therapy. High IgG (>
1750 mg/dL) levels and age over 60 y.o. at diagnosis were found to be related with the development of cancer.
When modelling the decision tree, patients with a delayed diagnosis and therapy were the most severe and with
higher risk of complications.
Conclusions: Our work confirms previous observations, highlights the importance of early diagnosis and therapy
and identifies new risk features such as high IgA and IgG levels for long-term complications.
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Introduction
Gaucher Disease (GD)(MIM#230800; MIM#231000;
MIM#230900) is the most common lysosomal storage
disorder (LSD) [1, 2]; some of the most common prob-
lems for GD patients are difficulty in diagnosis [3], ap-
pearance of complications, variability in the intensity of
symptoms and absence of curative treatments with de-
creased quality of life [4, 5]. Clinical characteristics of
GD are well established, but there remains a lack of in-
formation due to the singularity of the cases [6]. Also, it
has been impossible to define a complete phenotype-
genotype correlation [7–9] or to create a prognosis
model for complications. Because of these the initiative
to create registries has been developed by different insti-
tutions, research groups, and pharmaceutical companies;
allowing a continuous improvement in the knowledge of
the disease [10–12].
GD has a pan-ethnic distribution with cases described
worldwide. Outside the Ashkenazi Jewish population, in-
cidence ranges from 1 in 40,000 to 1 in 100,000 inhabi-
tants; however, in the Ashkenazi population a higher
incidence has been found (1 in 2500) and GD is not con-
sidered a rare disease [13]. Three types have been de-
scribed: type-1 GD (GD1; MIM#230800), or the non-
neuronopathic GD form, is the most common in west-
ern countries and it is characterized by the absence of
primary involvement in the central nervous system;
type-2 GD (GD2; MIM#230900) is the acute neurono-
pathic form with very severe cases, all of them with a
short lifespan of less than 2 years; and type-3 GD (GD3;
MIM#231000), or the juvenile/adult neuronopathic
form, described for first time in 1959 [14], is character-
ized by neurological affectation and also involvement of
other organs such as lungs, cardiac valves, and kyphosis,
among other manifestations [15–18].
The application of Enzymatic Replacement Therapy
(ERT), which began in 1991, has significantly improved
awareness of the disease, and has changed the character-
istics and expectations of patients as well as the experi-
ence of everyone involved in GD management.
Nowadays, ERT offers a secure therapy for GD patients
with 3 different available enzymes worldwide, two of
them in Europe (Imiglucerase, Sanofi-Genzyme and
Velaglucerasa alfa, Takeda pharmaceuticals), taliglucer-
ase alfa obtained from plant cell-expressed is until now
non approval in EU [19–22]. Since 2004, Substrate Re-
duction Therapy (SRT) has been developed for GD
treatment, first with one iminosugar (Miglustat, Actelion
Pharmaceuticls) and more recently with a ceramide mi-
metic (Eliglustat Tartatre, Sanofi-Genzyme) [23–25]
expanding the therapeutic options to GD patients. How-
ever, there is still the need to develop means of identify-
ing the small number of patients who are at risk of bone
crisis while receiving ERT, as well as those who are at
risk of developing late complications such cancer or
parkinsonism.
The Spanish Gaucher Disease Registry (SGDR) has
worked since 1993 to compile demographic, clinical,
genetic, analytical and imaging data of Spanish GD pa-
tients (currently numbering 361 GD1, 36 GD, and 21
GD3). The Registry has allowed us to calculate GD
prevalence in Spain (about 1/100,000 inhabitants) and to
identify the GBA (MIM*606463) variants distribution in
the population [12, 18].
In the last decades, the explosion of all kind of data
has driven to the use of different big data and machine
learning techniques for many applications in the health-
care and bioinformatics fields (several reviews can be
seen in references [26–28]. In particular the application
of computational tools and correlations network tech-
niques for the analysis of data can provide new insights
into the relationship between different variables and with
the disease, as well as informative and descriptive visual-
izations [28, 29]. The main objective of this project is to
identify new correlations among the patient characteris-
tics and to made a first approximation to the develop-




Since the establishment of the SGDR coordinated by the
Fundación Española para el Estudio y Terapéutica de la
Enfermedad de Gaucher y otras lisosomales (FEETEG), a
total of 418 GD patients have been reported in Spain.
All patients included in the SGDR provided informed
consent for the collection and use of the information
and biological samples for research projects, all accord-
ing to the Helsinki declaration of 1963 revised in Octo-
ber 2013, and in accordance with European Regulation
2016/679 on the protection of personal data and the free
movement of such data. For this study, ethics and scien-
tific FEETEG boards gave their approval.
All the registered patients were included except those
diagnosed with GD2 and those who had less than 70%
of baseline data available (Table 1). Of 418 patients in
the SGDR, 358 (85.6%) were analysed.
Study design
In collaboration with Kampal Data Solutions demo-
graphic, clinical, analytical, imagining data at diagnosis
and comorbidities during the follow-up were evaluated
(Table 1).
Variables: Birthdate, age at diagnosis, gender, con-
comitant diseases, family history of Parkinson disease
(PD), death date, severity category of disease according
to Gaucher Disease Severity Score System category (GD-
DS3) (mild, moderate, severe), liver size, spleen size,
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spleen removal, previous bone crisis and bone disease
degree according to the Spanish magnetic resonance
image score (S-MRI) (mild: 0–4; moderate: 5-8; severe >
9), bone mineral density (DEXA), GD biomarkers (chito-
triosidase activity (ChT), CCL18/PARC and Glucosil-
sphyngosine (GluSph) concentrations), B12 vitamin
level, iron concentration, serum ferritin, cholesterol, tri-
glycerides, high density lipoprotein cholesterol (HDL),
Low density lipoprotein cholesterol (LDL), aspartate
transaminase (AST), alanine transaminase (ALT),
gamma-glutamyl transferase (GGT), acid phosphatase,
bilirubin, hemoglobin concentration, white blood cells
(WBC) count, platelets count, serum gammaglobulin
fraction, immunoglobulins (IgG-, IgA-, IgM) -serum
concentrations, glucocerebrosidase (GCase) activity,
GBA genotype (NM_000157), presence of absence of the
variant NM_0003465:c.1049_1072dup24 on CHIT1, age
to start therapy, type of therapy (enzyme replacement
therapy (ERT) or substrate reduction therapy (SRT) or
no therapy, new bone crisis or joint replacement, devel-
opment of malignancies or PD, collected over a follow-
up period of 5 to 25 years.
The aimed conditions for which the analysis sought
correlations were the presence of severe bone disease at
diagnosis, development of bone crisis during follow-up,
and the development of neoplasia or PD.
Statistical analysis
The statistical analysis of the data was made in two parts.
Baseline data analysis
A descriptive analysis was performed by splitting the
variables between numerical and categorical. To estab-
lish correlation, Pearson, Chi-Square, Mann-Whitney
and Mann-Whitney normalized tests were used.
Prediction model
Based on the results of the first step and the correlation
between the different variables, we proceeded to the de-
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Age to start therapy years
Table 1 Variables (Continued)
Type of therapy ERT
SRT
N





S-MRI Spanish magnetic resonance score, DEXA Bone mineral density, GD-DS3
Severity category of GD, WBC white blood cell count, GCase
glucocerebrosidase, ChT Chitotriosidase, CCL18/PARC Chemokine ligand 18/
Pulmonary and activation-regulated chemokine, GluSph Glucosylsphyngosine,
PD Parkinson Disease
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To implement the models, a training and validation
cohort [30] were used, with application of the cross-
validation technique [31]. This allowed us to offer an es-
timate of errors. The models have been built only with
GD1 patients; GD3 patients have been ruled out because
they can die prematurely due to the severity of their dis-
ease. Standard quality metrics such as test sample size,
accuracy, sensitivity, specificity, odds ratio (OR), positive
predictive value (PPV), true positives (TP), true negatives
(TN), false positives (FP), false negatives, area under the
receptor operator curve (AUC) were calculated. Prepro-
cessing, data analysis and modelling were carried out
through the programming language R programming lan-
guage (version 3.6.2), by using, among others, the follow-




Most patients were GD1 (337 GD1; 94. 4%) and the rest
were GD3 (21, 5.6%). The most frequent GBA genotype
was complex heterozygosity (290; 81.0%) with the most
common variant being NM_000157:c.1226A > G (353/
716 alleles; 49.3%). Forty-seven GD1 patients (13. 9%)
were homozygous for c.1226A > G, and 9 GD3 patients
(42.8%) were homozygous for c.1448 T > C. Diagnosis
was made before the year 2000 for 168 (46. 9%) and 36
(10.1%) died before this study. Most of patients (193, 53.
9%) were treated with ERT. At diagnosis, 65 patients
(18.2%) were splenectomized, and 139 (38.89%) had ad-
vanced bone disease with bone complications. Regarding
comorbidities, 14 (4.1%) GD1 patients developed mono-
clonal gammopathy of undetermined significance
(MGUS), another 14 (4.1%) suffered PD, and 20 (5.6%)
malignant neoplasia (Table 2).
Correlations between numerical variables
A detailed correlation between the numerical variables
(Table S1) and categorical variables (Table S2) can be
found in supplemental material. A graph was con-
structed to provide a representation of how the different
variables are related to each other, not only in pairs but
in a global way (Fig. 1). In this graph, the nodes are the
different variables and a link is established between two
of them if the correlation (Pearson’s r) calculated be-
tween them is statistically significant (p ≤ 0.05). The
weight of the link is equal to the correlation between
the two variables. The position algorithm used for its
creation tries to place more closely those nodes that
are joined by stronger links, while those that are un-
related are further away. The highest correlation was
established between the age of diagnosis and the age
of onset of treatment. The statistical analysis was per-
formed in order to stablish correlation among all
variables, however, there were some correlations that
need to be taken carefully in an individualized man-
ner, in special the one involving baseline characteris-
tics and variables such as the age at diagnosis, time
Table 2 General characteristics
Characteristics Total: 358 100%
Mean age at diagnosis (range) 28.1 y.o. (87–0.5)
Mean age at therapy (range) 31.5 y.o. (1-83)
ChT activitya (range) 13,604.37 (67.0–65,497.01)
CCL18/PARC concentrationb (range) 590.52 (35–3895)
GluSph concentration c 34.02 (1.10–321.06)
Serum ferritin 568. 7 (14.0–2811.0)
S-MRI mean score (range) 11.0 (2-21)
N %
GBA genotype (NM_000157. 4) GD1d 337 94. 15
[c.1226A > G] + [c.1226A > G] 47 13.91
[c.1226A > G] + [c.1448 T > C] 113 33. 43
[c.1226A > G] + [other] 146 43. 19
[other] + [other] 31 9.47
GBA genotype (NM_000157. 4) GD3d 21 5.85
[c.1448 T > C] + [c.1448 T > C] 9 42.86
[c.1448 T > C] + [other] 7 33.33
[other] + [other] 5 23.81
Diagnosis
Index-case 276 76.88









Family history of PD 42 11.69
Development of PD 17 4.73
Spleen removal 65 18.10
Bone crisis during follow-up 81 22.56
Cancer and MGUS during follow-up 34 9.47
Other comorbidities 85 23.68
Dead 37 10.31
aChT activity was analyzed in 313 cases, ccases with double presence of
polymorphism in the gene encoding ChT (CHIT1; MIM*600031) associated with
a reduction in ChT activity, causing underestimation and consequent
misinterpretation and have not been considered in this section
bCCL18/PARC concentration was analyzed in 248 patients
cGluSph concentration was analyzed in 77 patients
dGBA genotype according with the reference sequence NM_000157. 4, other
variants meant no c.1266A > G, neither c.1448 T > C
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since diagnosis to therapy, time on therapy. At this
respect, for example, some patients did not start ther-
apy because the ERT was not available, and as conse-
quence their age at therapy correlates with the delay
of therapy.
Correlation between categorical variables
Table S2 from supplemental material shows the sig-
nificance of the correlation between the categorical
variables. There was a high correlation between
spleen removal and the presence of bone disease
(χ2n = 10.87, p < 0.01) and repeat bone crises (χ
2
n=
15.93, p < 0.01). Almost all of the patients who suf-
fered new bone crises had previous bone lesions
(χ2n = 30.47, p-value< 0.01).
Family history of PD and GBA genotypes no NM_
000157. 4:c.1226A > G in homozygosity were the
variables related to the development of PD (χ2n=
4.58, p < 0.01 in the correlation between having
PD’s or not and the set of 11 different genotypes).
The last correlation between categorial variables with
statistical significance was cancer development (not only
hematological) and spleen removal (χ2n = 3.80, p = 0.05)
(Fig. 2).
Correlation between numerical variables and conditions
To stablish correlation between the presence of con-
ditions such as severe bone disease, repeated bone
crisis, Spleen removal, Parkinson Disease and neopla-
sia with the numerical variables the normalized
Mann-Whitney test was used; for this two levels were
stablished, level 1 the absence of the condition and
level 2 the presence of the condition (Table S3 sup-
plementary material).
Bone disease
The numerical variables that showed the main rele-
vance for severe bone disease at diagnosis were the
S-MRI (Un = 0.98, p < 0.01) and IgA levels (Un =
0.93, p = 0.01), Table S3, supplemental material.
Nevertheless, there were other variables that
present relatively high correlations and low p-
values, such as high levels of ferritin (Un = 0.85, p =
0.06), triglycerides (Un = 0.75, p < 0.01), delayed age
at diagnosis (> 9.5y.o.) (p < 0.001), time in years be-
tween diagnosis and the start of treatment (Un =
0.67, p = 0.01) or delayed age of initiation of ERT
(Un = 0.61, p = 0.01) (Fig. 3A1).
The same happens with the appearance of successive
bone crises during ERT. The variables that correlate and
Fig. 1 Correlation network between numerical variables. Nodes are the variables and a link is established between them if correlation is
statistically significant (p-value ≤0.05). Those nodes that are joined by stronger links are placed closer, while those that are unrelated are further
away. GluSph: Lyso-glucosylsphingosine; Triglycer: serum triglycerides; Hct: hematocrit; Acid Phosphatase; Chol-HDL: cholesterol HDL, Chol-LDL
serum concentration: cholesterol LDL serum concentration; IgM: immunoglobuline M serum concentration; Tx: therapy; Delay Tx: time since
diagnosis to start of therapy
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Fig. 2 Correlation network between categorical variables, where the nodes are the different variables and a link is established between two of
them if the correlation calculated between them is statistically significant (p-value ≤0.05). Those nodes that are joined by stronger links are placed
closer, while those that are unrelated are further apart
Fig. 3 Correlation between numerical variables and bone disease. Histograms: A Correlation between S-MRI, IgA and age to start ERT and severe
bone disease. B Correlation between S-MRI, IgA and age to start ERT and repeat bone crisis
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have greater significance are S-MRI (Un = 0.92, p < 0.01),
high IgA levels (Un = 0.91, p = 0.08), and delayed age of
initiation of ERT (Un = 0.51, p = 0.07) (Fig. 3B1).
The analysis considering the mean age at diagnosis
minus the mean age to start therapy (Un = 0.62, p =
0.00001) (Table S3 Supplementary material)
(Fig. 4A2).
Neoplasia and Parkinson’s disease
High levels of IgG (Un = 0.91, p = 0.01) and time de-
lays before the start of therapy (mean age at diagno-
sis: 28.1 y.o. (0. 5-87); mean age at start therapy 31.5
y.o. (1-83); mean delay time: 7.8 years (0–46) (Un =
0.70, p = 0.00) were related to the development of
neoplasia (Fig. 4A).
In relation to the occurrence of PD, the numerical
variables that have a significant correlation were ele-
vated ferritin levels (Un = 0.92, p = 0.04) and age at
diagnosis (Un = 0.45, p = 0.01); in this last correlation
the age of PD onset probably has more weight
(Fig. 4B). The significant correlations are presented in
Table S3 of supplemental material.
Correlation between categorical variables
All correlations observed between categorical variables
are shown in Fig. 2.
High correlation were found between spleen removal
and the severe bone disease and repeated bone crises
(p = 0.0001). Almost all of the patients who suffered new
bone crises had previous bone lesions (p = 0.0005) in
spite of long-term ERT exposure.
The family history of PD and GBA genotypes other
than homozygous NM_000157.4:c.1226A > G were also
found to be statistically associated with PD development
(p < 0.01).
The last correlation between categorial variables with
statistical significance was cancer
development (not only hematological) and spleen re-
moval (p = 0.05) Fig. 2. (Table S2 supplementary
material).
Generation of predictive models for complications by
means of decision trees
Decision trees show the best prediction for the develop-
ment of severe bone disease in patients with an S-MRI
Fig. 4 Correlation between numerical variables with the development of neoplasia or Parkinson’s disease. Histograms: A Correlation between
increased serum IgG levels, time delay between GD diagnosis and the start of ERT with the development of neoplasia. B Correlation between
increased serum ferritin levels, age of GD diagnosis with the development of neoplasia
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> 2.5 who started therapy after 9.5 years; 87% of patients
with these characteristics developed a severe bone dis-
ease (Fig. 5).
For neoplasia, a higher risk was found when IgG >
1725 mg/dL and age of diagnosis > 60 y.o.
In the case of PD, it was not possible to design a tree
that improves the prediction of the risk of disease devel-
opment, because the percentage of patients was very
small. However, it has been observed that there is an im-
portant correlation with the GBA genotype (p < 0.01)
and also with the existence of relatives with PD (p =
0.08), although this was not statistically significant. In
the supplemental material, Tables S3-S4 show the statis-
tical significance of correlation among the selected vari-
ables used for the algorithms.
Discussion
Large-scale data (big data) in our case when referring to
a rare disease have been adapted to the number of cases
available; this kind of analysis is a new tool that has re-
cently been incorporated into biomedical activity; ma-
chine learning is the study of computer algorithms that
improve automatically through experience and it in-
volves a wide series of algorithms, classification and
regression models such as decision trees being some
of them [26–29]. This methodology is especially
useful for obtaining pooled information on the di-
versity of outcomes and identifying prognostic
factors potentially related to disease complications
[35]. In rare disease research, this is of particular
interest due to the scarcity and the spread of the
data among the different centers [36]. Various ap-
proaches have been applied in the area of rare dis-
eases, especially in looking for genetic associations
[37] and making correlations between genotype and
phenotype [38].
Registries have an important role in this kind of ana-
lysis, because they include complete information about
patients, which is especially important for rare disease
research. This collected information helps in diagnosis,
patient management, treatment strategy planning, health
care planning and follow-up. It enables the acceleration
of research and paves new pathways for personalized
medicine [39, 40].
This study is the first attempt to establish a correlation
network among different biochemical and clinical char-
acteristics in a national-base cohort. We have aimed to
analyse diagnostic data and to relate them with long-
term complications as bone crises, development of neo-
plasia or PD, which are the most common and disabling
complications [41–45].
Two observations, already accepted in Gaucher re-
search, were also confirmed in this machine-learning
study: first, the fact that spleen-removal patients have a
higher risk of presenting more serious and extensive
bone disease; second, our observation that almost all
Fig. 5 Decision tree related to the development of bone disease. The information that appears in each node includes (top down): the value of
the target variable assigned by the algorithm: develops bone disease: yes/no. the ratio of patients in this node who had (left) / did not have
(right) bone disease. percentage of the total population included in this node. For the prediction of bone complications, a mild bone marrow
infiltration of 2.5 points by the Spanish Magnetic Resonance Imaging Score (S-MRI) with the delay of the start therapy over an age 9.5 years were
the two characteristics selected by the prediction model
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patients with new bone crisis – despite having received
long-term ERT – had previous bone lesions, which re-
mind us that the most feared complication in GD1 are
not solved merely by starting ERT. These two facts con-
firm previous reports and provide validity of our analysis
[42, 45–47]. In addition, genotypes different from homo-
zygous NM_000175. 4:c.1226A > G are significantly cor-
related with bone disease (p = 0.05). This last
observation is in line with the observation that
c.1226A > G variant provides a mild phenotype [48, 49].
It is a priority to identify accurate risk factors of bone
crisis to improve treatment dosage and to avoid this
complication. The standard biomarkers related to GD
(ChT activity, CCL18/PARC and GluSph concentra-
tions) have been discarded as risk factors for bone com-
plication [50, 51] even though their concentration will
be increased during bone crisis, due to the acute inflam-
matory event [45, 49]. This reminds us of the import-
ance to continue searching for other biomarkers. Our
results confirm the lack of association between these
biomarkers and disease outcomes, but other biomarkers,
such as high levels of ferritin, show a tendency in pa-
tients with advanced bone disease although it was not
statistically significant.
Surprisingly, the high serum IgA concentration cor-
relates with the degree of bone involvement and with
the development of bone crisis (p = 0.001). The age of
onset of treatment (mean 30.6 y.o.) (p = 0.01) also
shows a clearer relevance for the occurrence of bone
crises (p = 0.01).
In this study, the development of malignancies appears
strongly correlated with the delayed age at the start of
ERT (p < 0.01) and the increased concentration of IgG
(p = 0.01). Many aspects remain to be unraveled in the
complexity of the immune system, but aging is an im-
portant factor clearly related to humoral immune dys-
function and the appearance of malignancies [52].
Polyclonal and monoclonal gammopathies in GD pa-
tients are common [53] and we observed a significant
correlation between high levels of IgG and the appear-
ance of neoplasia [54]. However, the origin of these al-
terations is not fully clarified, and is attributed to the
chronic inflammation state; also, it is related to an in-
crease in levels of inflammatory cytokines such as inter-
leukins (IL-6, IL-10) that could lead to an
overproduction of immunoglobulins [53, 54]. Another
hypothesis could be that B lymphocytes were activated
by specific type II natural killer T lymphocytes, with a T
follicular helper profile, and that the clonal immuno-
globulin in GD patients and in mouse models of GD was
reactive against GluSph [55].
The identification of levels of IgA as a risk factor
for complication was a surprising finding; it has not
been previously reported that IgA levels are related to
severe bone disease and the presence of repeated
bone crises in GD.
Also, our data, shown an analysis of the main clinical
features of GD patients at diagnosis; in accordance with
previous reports [2, 6, 10–12], general characteristics
such as polyclonal gammopathies, bone pain, bone vas-
cular lesions, hypertriglyceridemia, splenomegaly and
family history of parkinsonism, would be findings that
can help to identify GD patients.
The SGDR only includes GD patients from Spain, thus
the main limitations for the study are the absence of a
larger data set. Despite this, the included data reflect the
characteristics of the disease in this country. It could be
interesting to validate these findings by studying other
populations with a greater number of patients; however,
taking into account the homogeneity of the series and
the single-country origin, the data are solid.
Conclusions
Our work confirms previous observations such as the re-
lationship among bone disease and splenectomy; it high-
lights the importance of early diagnosis and therapy and
identifies new risk features such as high IgA and IgG
levels for long-term complications. This is first attempt
in which all the baseline diagnosis data has been in-
cluded in a study to perform analysis of network correla-
tions. This open the possibility to move forward using
nowadays technology; it will help us to identified fea-
tures that can predict risk for complications or maybe, if
more patients can be included, a better phenotype-
genotype correlation.
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Reduction Therapy; TP: True positive; Tx: Therapy; WBC: White blood cells
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